Ubs Asset Management Americas Inc Clovis Oncology, Inc. Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

17 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$0.63 - $2.96 $61,860 - $290,645	-98,191 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$4.06 - $5.8 $118,450 - $169,215	-29,175 Reduced 22.91%	98,191 $437,000
Q2 2021 Aug 16, 2021	BUY	$5.02 - $7.05 $251,813 - $353,642	50,162 Added 64.97%	127,366 $738,000
Q1 2021 May 14, 2021	SELL	$4.81 - $10.34 $14,021 - $30,141	-2,915 Reduced 3.64%	77,204 $541,000
Q4 2020 Mar 01, 2021	BUY	$4.13 - $6.41 $8,701 - $13,505	2,107 Added 2.7%	80,119 $384,000
Q3 2020 Nov 13, 2020	SELL	$4.82 - $7.72 $8,401 - $13,455	-1,743 Reduced 2.19%	78,012 $454,000
Q2 2020 Aug 14, 2020	BUY	$5.69 - $9.69 $453,805 - $772,825	79,755 New	79,755 $538,000
Q4 2019 Feb 14, 2020	SELL	$3.0 - $16.43 $168,555 - $923,119	-56,185 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$3.93 - $15.35 $67,352 - $263,068	17,138 Added 43.89%	56,185 $220,000
Q2 2019 Aug 15, 2019	BUY	$12.81 - $25.67 $58,554 - $117,337	4,571 Added 13.26%	39,047 $0
Q1 2019 May 14, 2019	BUY	$17.66 - $30.28 $275,266 - $471,974	15,587 Added 82.52%	34,476 $0
Q4 2018 Feb 13, 2019	SELL	$11.63 - $32.67 $1.03 Million - $2.89 Million	-88,452 Reduced 82.4%	18,889 $339,000
Q3 2018 Nov 14, 2018	BUY	$29.37 - $49.48 $65,730 - $110,736	2,238 Added 2.13%	107,341 $0
Q2 2018 Aug 14, 2018	SELL	$42.06 - $62.4 $13.2 Million - $19.7 Million	-315,002 Reduced 74.98%	105,103 $0
Q1 2018 May 14, 2018	SELL	$50.12 - $67.72 $6.61 Million - $8.94 Million	-131,977 Reduced 23.91%	420,105 $0
Q4 2017 Feb 09, 2018	BUY	$57.69 - $84.58 $10.3 Million - $15.1 Million	178,337 Added 47.72%	552,082 $0
Q3 2017 Nov 13, 2017	BUY	$67.17 - $84.81 $25.1 Million - $31.7 Million	373,745	373,745 $0

Others Institutions Holding CLVS

# of Institutions

Shares Held

166

Call Options Held

Put Options Held

Exane Derivatives

166
Shares

$14
0.0% of portfolio

View Full List

About Clovis Oncology, Inc.

Ticker CLVS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 144,480,000
Market Cap $13M
Description
Clovis Oncology, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. In the U.S., the company offers Rubraca (rucaparib), an oral small molecule inhibitor of poly ADP-ribose polymerase for recurrent epithelial ovarian, fallopian tube, or pr...

More about CLVS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account